Christie Ballantyne, MD
Cardiovascular Disease · Houston, TXNPI 1467471557
Payments from drug & device makers
Across 513 payments — averaging $8915.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1.7M
- Amgen$620K
- Eli Lilly$537K
- Novartis$498K
- Roche Diagnostics Corporation$400K
- Akcea Therapeutics, Inc.$242K
- plus $534K from 24 others
Across 15 payments — averaging $9555.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$120K
- Novartis$11K
- Amgen$7K
- Regeneron$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $1,742,356 |
| Amgen | 70 | $619,894 |
| Eli Lilly | 80 | $537,010 |
| Novartis | 28 | $498,446 |
| Roche Diagnostics Corporation | 2 | $399,853 |
| Akcea Therapeutics, Inc. | 7 | $241,638 |
| Regeneron | 38 | $167,987 |
| Ionis Pharmaceuticals, Inc. | 34 | $114,440 |
| Merck | 83 | $70,143 |
| Amarin Pharma, Inc. | 40 | $38,488 |
| Roche Diagnostics International Ltd | 7 | $26,734 |
| Novo Nordisk | 16 | $24,391 |
| Sanofi-aventis U.S. LLC | 15 | $20,479 |
| AstraZeneca | 13 | $14,518 |
| Esperion Therapeutics, Inc. | 5 | $9,013 |
| Pfizer | 7 | $8,400 |
| Novartis Pharma AG | 4 | $8,366 |
| Genentech, Inc. | 2 | $5,314 |
| Intercept Pharmaceuticals, Inc. | 3 | $4,940 |
| Gilead | 5 | $4,025 |
| Astrazeneca UK Limited | 4 | $3,622 |
| Alnylam Pharmaceuticals Inc. | 1 | $3,525 |
| Upjohn US 1 LLC | 1 | $3,500 |
| CSL Behring | 2 | $3,195 |
| Heartflow, Inc. | 1 | $1,800 |
| Boehringer Ingelheim International GmbH | 1 | $1,375 |
| Medtronic | 1 | $129 |
| Johnson & Johnson | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$4,573,642 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Houston
- Syed NaqviHouston$3.6M
- James FeldmanHouston$3.1M
- Aditya SamalHouston$2.6M
- Pranav LoyalkaHouston$2.4M
- Anwar AhmadHouston$1.4M
- Reynolds DelgadoHouston$1.1M
- Richard SmallingHouston$908K
- Amin KarimHouston$853K
- Stephen LittleHouston$806K
- Joggy GeorgeHouston$634K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.